ETHACIZINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H27N3O3S.ClH
Molecular Weight	449.994
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN(CC)CC)C=C1

InChI

InChIKey=VHNXQKLWIQHSOY-UHFFFAOYSA-N

InChI=1S/C22H27N3O3S.ClH/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3;/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27);1H

HIDE SMILES / InChI

Molecular Formula	C22H27N3O3S
Molecular Weight	413.533
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15798717

Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other Commonwealth of Independent States countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cardiac muscle cell action potential 2 Target ID: GO:0086001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2538064	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Atrial fibrillation 131 Sources: https://www.rlsnet.ru/tn_index_id_5522.htm	Primary		Approved 8429	Ethacyzin Approved Use Unknown
Wolff-Parkinson-White syndrome 5 Sources: https://www.rlsnet.ru/tn_index_id_5522.htm	Primary		Approved 8429	Ethacyzin Approved Use Unknown

PubMed

Title	Date	PubMed
Ethacizin metabolism in humans.	1989 Jul	2773511
[Atrial fibrillation: choice of the method of pharmacological cardioversion].	2005	15798717

Patents

Sample Use Guides

In Vivo Use Guide

The initial dose is 50 mg (1 table) 2-3 times a day. In case of insufficient clinical effect, the dose is increased (under compulsory ECG monitoring) to 50 mg 4 times a day (200 mg) or 100 mg 3 times daily (300 mg).

Route of Administration: Oral

In Vitro Use Guide

Ethacizine applied in the concentration range between 1 X 10(-7) and 1 X 10(-5) g/ml decreased the rate of action potential growth (Vmax) of the mammal myocardium. Inhibition of the Vmax was accompanied by the diminution of the force of contraction which involved two phases. Ethacizine also decreased the overshoot of slow response action potential with the time constant similar to that in the first rapid phase of force reduction.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:43:16 GMT 2023` Edited by `admin` on `Sat Dec 16 01:43:16 GMT 2023`
Record UNII	260059T81O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETHACIZINE HYDROCHLORIDE

Common Name

English

ETHYL 10-(3-(DIETHYLAMINO)PROPIONYL)PHENOTHIAZINE-2-CARBAMATE HYDROCHLORIDE

Common Name

English

CARBAMIC ACID, (10-(3-(DIETHYLAMINO)-1-OXOPROPYL)-10H-PHENOTHIAZIN-2-YL)-, ETHYL ESTER, MONOHYDROCHLORIDE

Common Name

English

Ethacizine hydrochloride [WHO-DD]

Common Name

English

ETHACIZIN HYDROCHLORIDE

Common Name

English

ETACIZIN HYDROCHLORIDE

Common Name

English

Code System Code Type Description

FDA UNII

260059T81O